ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Receives Consensus Rating of “Moderate Buy” from Brokerages

Shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) have earned a consensus rating of “Moderate Buy” from the nine brokerages that are currently covering the stock, Marketbeat reports. Three analysts have rated the stock with a hold recommendation and six have issued a buy recommendation on the company. The average 1 year price target among brokerages that have updated their coverage on the stock in the last year is $103.4286.

ANIP has been the topic of several recent research reports. Truist Financial upped their price objective on shares of ANI Pharmaceuticals from $77.00 to $90.00 and gave the company a “hold” rating in a report on Thursday, October 9th. Weiss Ratings reaffirmed a “hold (c+)” rating on shares of ANI Pharmaceuticals in a report on Monday, December 29th. Barclays started coverage on ANI Pharmaceuticals in a research report on Tuesday, December 9th. They set an “overweight” rating and a $100.00 price target on the stock. Guggenheim boosted their price objective on ANI Pharmaceuticals from $115.00 to $124.00 and gave the company a “buy” rating in a report on Friday, January 16th. Finally, Zacks Research downgraded ANI Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, January 6th.

ANI Pharmaceuticals Stock Down 0.2%

Shares of ANIP stock opened at $81.85 on Friday. ANI Pharmaceuticals has a fifty-two week low of $54.10 and a fifty-two week high of $99.50. The firm has a market capitalization of $1.84 billion, a PE ratio of 50.21 and a beta of 0.51. The company has a debt-to-equity ratio of 1.20, a quick ratio of 2.04 and a current ratio of 2.58. The stock’s 50-day simple moving average is $81.90 and its 200-day simple moving average is $84.94.

ANI Pharmaceuticals (NASDAQ:ANIP) last issued its earnings results on Friday, November 7th. The specialty pharmaceutical company reported $2.04 EPS for the quarter, beating analysts’ consensus estimates of $1.74 by $0.30. ANI Pharmaceuticals had a return on equity of 26.73% and a net margin of 4.91%.The firm had revenue of $227.81 million for the quarter, compared to analyst estimates of $211.92 million. During the same quarter in the prior year, the firm earned $1.34 earnings per share. ANI Pharmaceuticals’s revenue for the quarter was up 53.6% on a year-over-year basis. ANI Pharmaceuticals has set its FY 2025 guidance at 7.370-7.640 EPS. Equities analysts expect that ANI Pharmaceuticals will post 3.86 earnings per share for the current year.

Insiders Place Their Bets

In other news, SVP Chad Gassert sold 14,642 shares of the firm’s stock in a transaction that occurred on Wednesday, November 12th. The shares were sold at an average price of $89.07, for a total transaction of $1,304,162.94. Following the sale, the senior vice president owned 158,584 shares of the company’s stock, valued at $14,125,076.88. This trade represents a 8.45% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, SVP Krista Davis sold 1,622 shares of the business’s stock in a transaction on Thursday, December 18th. The shares were sold at an average price of $82.40, for a total transaction of $133,652.80. Following the completion of the transaction, the senior vice president owned 58,564 shares of the company’s stock, valued at approximately $4,825,673.60. This represents a 2.69% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders have sold 28,101 shares of company stock worth $2,453,063. Corporate insiders own 11.10% of the company’s stock.

Institutional Investors Weigh In On ANI Pharmaceuticals

Several hedge funds have recently modified their holdings of ANIP. Advisors Asset Management Inc. purchased a new position in shares of ANI Pharmaceuticals in the 1st quarter valued at about $28,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in shares of ANI Pharmaceuticals by 4.5% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 10,993 shares of the specialty pharmaceutical company’s stock valued at $736,000 after buying an additional 470 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its position in shares of ANI Pharmaceuticals by 0.9% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 48,322 shares of the specialty pharmaceutical company’s stock valued at $3,235,000 after buying an additional 423 shares in the last quarter. Jane Street Group LLC acquired a new position in shares of ANI Pharmaceuticals during the 1st quarter worth approximately $2,706,000. Finally, State of Alaska Department of Revenue lifted its position in shares of ANI Pharmaceuticals by 10.0% during the 2nd quarter. State of Alaska Department of Revenue now owns 10,116 shares of the specialty pharmaceutical company’s stock valued at $659,000 after buying an additional 920 shares in the last quarter. 76.05% of the stock is owned by hedge funds and other institutional investors.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.

ANI’s product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.